Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Merger or Acquisition (August 2020)
21 slides from Sanuwave Health's merger presentation, Aug 12, 2020
Slide 1: SANUWAVE Acquisition Update
SANUWAVE | Acquisition Update "August 12, 2020
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the Company's current views with respect to certain current and future events and financial performance. Forward-looking state
Slide 3: SANUWAVE Acquires Celularity's UltraMIST and Partnership Rights for $24 Million
SANUWAVE O CO celularity SANUWAVE Health, Inc. Acquires Celularity’s UltraMIST ° and Partnership Rights for Wound Care Biologic Products for $24 Million Key -fad 1 al Broadens wound care platform Provides end-to-end advanced Enhances SANUWAVE’s financial with non-contact ultrasound wound care offeri
Slide 4: Transaction Rationale
Transaction Rationale Transaction Overview Combination of SANUWAVE and Celularity’s wound care assets creates a market-leading provider of advanced wound care solutions that improves clinical outcomes across the continuum of care Investment Thesis Combine two highly complementary energy transfer tec
Slide 5: Transaction Overview
Transaction Overview Transaction and Financing Highlights = Purchase price: = Transaction terms: * EBITDA multiple: = Financing: $24 million $20 million cash plus a $4 million seller note 6x adjusted EBITDA (2019) 4x first year EBITDA, including year 3 run rate cost synergies Proceeds of $44.4 milli
Slide 6: Combined Company Overview
4 | BN —— | ® Combined C SANUVVAVE | werview or”
Slide 7: Combined Company Overview
Combined Company Overview Combined Company Overview Acquired assets generated $15M in revenue and $4M in adjusted EBITDA in 2019 with cost savings opportunities Highlights * Compelling cross-selling opportunities with 1,000+ combined accounts, with only 15 overlapping * 100 “Feet on the Street”: 20
Slide 8: SANUWAVE Will Address Entire Advanced Wound Care Continuum
Combined Company Overview SANUWAVE Will Address Entire Advanced Wound Care Continuum Acute Wound Care Chronic / Advanced Wound Care Treatment Options Weeks 1-2 Weeks 2-4 Weeks 3-5 Weeks 4-6 Weeks 5-12+ Home Treatment Standard of Care Initial Visit & Treatment Continue Treatment Treatment & Closure S
Slide 9: Large Total Addressable Market in the United States
Combined Company Overview Large Total Addressable Market in the United States By combining SANUWAVE and the Celularity Wound Care assets, SANUWAVE is targeting a ~$45 billion market in the US 1. H H ~$45 Billion | ‘li { 2,200 Estiveated Annual Wourl Carel} ~$15 Billion . H Wound Care Centers in the
Slide 10: Sales & Marketing Synergies
Combined Company Overview Sales & Marketing Synergies Compelling cross-selling opportunities with common call points and 1,000+ combined accounts with only 15 overlapping Existing Strengths and Overlap Cross-Selling Opportunities © Combination ey Mrectinnd + Significant cross-selling opportunities t
Slide 11: U.S. Sales Force
U.S. Sales Force Combined Company Overview Powerful combined sales force coverage and organization with over 1,000 existing accounts expected to grow to 3,000 Sales Force Overview Direct * 20 direct sales representatives + Average revenue per rep ranges: $500k to $1.5M * Significant pipeline of woun
Slide 12: SANUWAVE Health Overview
as.5 SANILIVVAV/E’ | sanuwave Health overview \ SermaPACE Ws
Slide 13: The dermaPACE System Overview
SANUVWAVE Overview The dermaPACE® System Overview The dermaPACE® System positions SANUWAVE for continued success in large and emerging markets Product Overview Mechanism of Action Indications for Use + The dermaPACE® System is a non-invasive FDA Approved device for the repair and regeneration of ski
Slide 14: Overview of Celularity's Wound Care Business
Overview of Celularity’ s SANUWAVE:
Slide 15: Celularity's Wound Care Portfolio at a Glance
CPD celutority Wound Care Overview Celularity’s Wound Care Portfolio at a Glance Products focused on promoting natural healing and offering a clinically proven solution even in cases where standard of care has failed Company Snapshot * Leading suite of natural wound healing products Product * Device
Slide 16: UltraMIST Overview
COD cetutority Wound Care Overview UltraMIST Overview UltraMIST expands SANUWAVE’s addressable market with treatment of additional acute and chronic wounds Product Overview FDA Approved Indications * Alow-frequency, non-contact ultrasound energy delivered through a fluid mist Diabetic Foot Ulcers =e
Slide 17: Celularity's Biologic Products
Celularity’s Biologic Products BIOVANCE’ ara Arte Hembra Ase COD cetutority Wound Care Overview Interfyl eran Connective Taaue Matix Overview * Provides a natural foundation for wound healing * Key cells and proteins move into the BIOVANCE material promoting tissue regeneration and wound healing * S
Slide 18: Celularity Wound Care Product Reimbursement
COD cetutority Wound Care Overview Celularity Wound Care Product Reimbursement Code: Description: Fees:(!) Additional Detail: UltraMIST. BIOVANCE Interfyl | Utrasound Heling Therapy eters eens oe [ woran Connective Tas Mati CPT Code 97610 HCPCS Code Q4154 HCPCS Code Q4171 Low frequency, noncontact n
Slide 19: Growth Strategy
Slide 20: Foundation for Sustained Growth
Growth Strategy Foundation for Sustained Growth Building on a strong foundation, SANUWAVE would have multiple avenues to drive continued, sustained growth Other Medical and Non-Medical Applications * Capitalize on other medical markets - orthopedicsyiill “~ pain, plastic surgery, and vascular / card
Slide 21: Conclusion
Conclusion Conclusion = Broadens Commercial Infrastructure and “Feet on the Street” to 100 Sales Resources = Significant Cross-Selling Opportunities: 1,000+ Accounts with Only 15 Overlapping * Innovative, Patent-Protected Technologies Supporting a Strong Wound Care Product Portfolio = End-to-End Adv
SANUWAVE Health — Merger or Acquisition (August 2020) on 6ix